← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Net income decreased 878.8% to ($209.8M), while Operating cash flow increased 63.9% to ($6.7M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($209.8M)Watch
- Cash generation — Free cash flow ($6.7M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 0 buys; 3 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Damora Therapeutics, Inc.: We are a preclinical stage biotechnology company with a limited operating history on which to assess our business; we have no products that have been administered to humans or approved for commercial sale, which may make it difficult to evaluate our current business and likelihood of success and viability.
Leadership changes
From Damora Therapeutics, Inc.'s own filings, the day they're filed.
- Brian Burkavage · principal financial officer · appointmenteff. 2026-04-28
- Jennifer Jarrett · President · appointmenteff. 2026-03-30
- K. Effective · directors · appointmenteff. 2026-03-23
Latest filings
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-07-20
- 8-K · Company announcement2026-06-17
- 10-Q · Quarterly report2026-05-12
- 8-K · Company announcement2026-05-04
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Damora Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.